Bristol/Pfizer Offer Some Good Apixaban Results, With Key Study Against Warfarin On Track To Report 2H 2011
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb/Pfizer got incremental good news and a nice addition to the safety database for their experimental anticoagulant apixaban when a Phase III study was ended early for efficacy at preventing stroke compared to aspirin. The next big read-out for the oral Factor Xa inhibitor, though, will be in the first half of 2011, when results of a major head-to-head contest against warfarin in that setting are due